References

I-178

1. **Buton BK, Balwani M, Feillet F, et al. A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency. *N Engl J Med*.2015;1010-20.**
2. **Erwin AL. The role of sebelipase alfa in the treatment of lysosomal acid lipase deficiency. *Ther Adv Gastroenterol*. 2017;553-562.**
3. **MICROMEDEX®SOLUTIONS Compendia.2020. Sebelipase alfa.**
4. **Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Sebelipase alfa.2020.**
5. **KANUMA (sebelipase alfa) Intravenous Infusion [package insert]. Alexion Pharmaceuticals Inc. New Haven, CT, 01/2015. Revised 12/2015.**
6. **Jones SA, Rojas-Caro S, Quinn AG, Friedman M, Marulkar S, Ezgu F, et al. Survival in infants treated with sebelipase alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study. *Orphanet Journal of Rare Diseases*. 2017; 12(25):1-12.**
7. **MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).**
8. **Jones, S. A., Valayannopoulos, V., Schneider, E., et al. Rapid progression and mortality of lysosomal acid lipase deficiency presenting in infants. Genet Med. 2016 18(5), 452-458.**
9. **Patterson, C., So, S., DeAngelis, M., Ghent, E., Southmayd, D., & Carpenter, C. Physical activity experiences in children post–liver transplant: Developing a foundation for rehabilitation interventions. Pediatr Transplant. 2018. 22(4), e13179.**